Galicia launches a pioneer project against DMAE

Galicia It will begin a pioneering project to measure the real impact of innovative treatments on the lives of patients suffering from macular degeneration associated with age.

The implementation of this project in the Sergaswas approached by the president of the Xunta, Alfonso Ruedaaccompanied by the Minister of Health, Antonio Gómez Caamaño, and the executive director of Roche Pharma International, Padraic Ward, in a work meeting.

This collaboration is part of the bet of the Xunta and Roche Pharma for promoting the measurement of the social effect of health interventions related to macular degeneration associated with age, a disease that It affects more than 40,000 people in Galicia and that is the main cause of blindness in over 65 years.

Within the framework of the agreement, the possible realization of Population screening with Artificial Intelligence ToolsDevelop training programs for health professionals in ophthalmology research and implement digital solutions for home assistance of patients with macular degeneration associated with age.

In this way, the Sergas, in collaboration with Roche, will develop an precise system for the measurement of health results that seeks Transform health care to improve care for patients and their families.

The results measurement system will allow a Advanced evaluation which will result in the optimization of management and strengthening clinical decisions, in addition to allowing a narrower and more personalized monitoring of patients.

In patients with associated macular degeneration, they propose, in the future, the design of a Comprehensive Project for the Improvement of the Assistance Process, Starting from a population screening based on artificial intelligence tools that will be developed throughout the different phases of the disease approach: diagnosis, treatment and follow -up, including remote patient monitoring and the incorporation of health results.

During the meeting, the executive director of Roche Pharma International, Padraic Ward, said that this agreement “It will place Galicia to the world avant -garde in the DMAE approach and other diseases of the retina supported by the measurement of health results and the social value of innovation. “